NVP-2203 is under clinical development by NVP Healthcare and currently in Phase III for Hypercholesterolemia. According to GlobalData, Phase III drugs for Hypercholesterolemia have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how NVP-2203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NVP-2203 overview

NVP-2203 is under development for the treatment of primary hypercholesterolemia and dyslipidemia. It is administered through oral route as tablets.

NVP Healthcare overview

NVP Healthcare formerly Navipharm, develops novel pharmaceuticals products and microbiomes. NVP Healthcare is headquartered Suwon, Gyeonggi, South Korea.

For a complete picture of NVP-2203’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.